二、交易概述 证券代码：301408 证券简称：华人健康 公告编号：2023-041 安徽华人健康医药股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、特别提示 1、安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"） 拟通过支付现金方式购买自然人王祥安、浙江自贸区雪源项目投资合伙企业（有 限合伙）（以下合称"交易对方一"）合计持有的舟山里肯医药连锁有限公司（ 以下简称"舟山里肯"）60%的股权及购买嘉兴乾达创业投资合伙企业（有限合 伙）（以下简称"交易对方二"）持有的嘉兴市老百姓药品零售有限公司（以下 简称"嘉兴老百姓"）70%的股权（以下合称"本次交易"或"本次收购"）。 公司于2023年7月12日在巨潮资讯网（www.cninfo.com.cn）发布的《安徽华人健 康医药股份有限公司关于筹划重大资产重组的提示性公告》已对本次交易涉及的 有关风险因素及尚需履行的审批程序进行了详细说明。 2、截至本公告披露日，除本次交易提示性公告披露的风险外，公司尚未发 现可能导致公司或者交易对方撤销、中止本次交易 ...

证券代码：301408 证券简称：华人健康 安徽华人健康医药股份有限公司 投资者关系活动记录表 编号：2023-002 特定对象调研 ☐分析师会议 ☐媒体采访 ☐业绩说明会 投资者关系活动类 别 ☐新闻发布会 ☐路演活动 现场参观 其他（电话会议） 华泰证券：孔垂岩、王殷杰 东方证券自营：刘迎 东北证券：文将儒 泰康资管：贺一 参与单位名称及 人员姓名 东证资管：邹秉昂 银华基金：戴方贤 睿郡资产：魏志华 东吴资管：陆一韬 时间 2023年07月21日 10:00-12:00 地点 公司6楼会议室及电话会 董事长、总经理 何家乐先生 董事、副总经理 何家伦先生 上市公司接待人员 姓名 董事会秘书、财务总监 李梅女士 投资总经理 王军先生 证券事务代表 黄莲莲女士 一、此次省外拓展为何选择浙江为重点突破口？ | --- | |----------------------------------------------------------------| | 1、浙江省是全国共同富裕先行示范区，经济基础好，人口基数 | | 大，消费购买力强，单店产出较高；公司本次以浙江省为突破口，将进 | | 一步实现公司零售 ...

安徽华人健康医药股份有限公司 投资者关系活动记录表 证券代码：301408 证券简称：华人健康 编号：2023-001 6.公司是有自己的仓储和配套物流，还是有相应的服务商配 套。 答:尊敬的投资者您好，公司已在合肥、亳州分别建立了集中 仓库，统一运营、统一调配。零售门店的配送需求，公司根据统一 的物流规划安排，自行安排配送（通过仓储部或汇达药业），或者 通过第三方物流进行配送。所有门店的配送均在总部的统一管理下 有序进行，仓库与各门店之间配送半径规划合理，能够快速高效地 响应门店需求。公司制定了仓储配送相关管理制度和流程。公司通 过ERP系统和WMS系统、客户管理系统（CRM）和电子商务系统，实 现信息流、物流、商流的集中控制管理，有效提供配送效率，感谢 您的关注！ 7.收购马鞍山曼迪新大药房连锁有限公司 重组后新公司51% 股，目前到哪一步了～ 答:尊敬的投资者您好，公司将根据项目进展情况及时公告， 请您届时关注公司公告，谢谢！ 8.公司有自己的药品研发团队吗？ 答:尊敬的投资者您好，基于公司代理板块的全国营销网络， 公司积极布局自有商品，通过自研、委外，购买等多种方式获得药 | 投资者关系活动类别 | ...

Financial Performance - The company's revenue for Q1 2023 reached ¥845,614,829.78, representing a 24.91% increase compared to ¥676,978,835.10 in the same period last year[5] - Net profit attributable to shareholders was ¥29,483,336.47, a significant increase of 90.94% from ¥15,441,235.95 in the previous year[5] - Basic and diluted earnings per share increased by 80.40%, reaching ¥0.0819 per share, up from ¥0.0454 per share in the prior year[5] - Total operating revenue for Q1 2023 reached ¥845,614,829.78, an increase of 25% compared to ¥676,978,835.10 in Q1 2022[28] - Net profit for Q1 2023 was ¥29,158,078.38, representing a 89.5% increase from ¥15,393,421.16 in Q1 2022[29] - Basic and diluted earnings per share for Q1 2023 were both ¥0.0819, compared to ¥0.0454 in Q1 2022, marking an increase of 80.5%[30] Cash Flow and Liquidity - The net cash flow from operating activities surged by 198.46%, amounting to ¥205,224,849.16 compared to ¥68,760,834.52 in Q1 2022[5] - Cash inflow from operating activities totaled CNY 966,968,925.08, compared to CNY 531,308,574.21 in the previous period, indicating a rise of about 82.0%[33] - Cash outflow from operating activities increased to CNY 761,744,075.92 from CNY 462,547,739.69, reflecting a growth of approximately 64.6%[33] - The net cash flow from investing activities was CNY -134,666,915.68, worsening from CNY -27,291,232.81 in the previous period[33] - Total cash and cash equivalents at the end of the period amounted to CNY 974,774,620.88, compared to CNY 62,179,722.89 at the end of the previous period, indicating a substantial increase of approximately 1465.5%[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,614,598,263.03, reflecting a 40.31% increase from ¥2,576,184,947.30 at the end of the previous year[5] - Total liabilities increased to ¥1,755,989,375.54 in Q1 2023 from ¥1,629,179,024.60 in Q1 2022, a rise of 7.8%[26] - The company's equity attributable to shareholders reached ¥1,858,348,878.58, significantly up from ¥947,278,655.70 in the previous year, reflecting a growth of 96.3%[26] Research and Development - The company's R&D expenses rose dramatically by 705.83%, totaling ¥2,027,569.40, compared to ¥251,612.14 in the same quarter last year, indicating increased investment in innovation[9] - Research and development expenses for Q1 2023 were ¥2,027,569.40, compared to ¥251,612.14 in Q1 2022, showing a substantial increase of 705.5%[28] Shareholder Information - The major shareholder, He Jiale, holds 50.12% of the shares, totaling 200,493,326 shares[12] - Alibaba Health Technology (China) Co., Ltd. is the second-largest shareholder with 7.51%, holding 30,049,373 shares[12] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[12] - The total number of restricted shares held by He Jiale is 200,493,326, which will be released on March 1, 2026[14] - The company reported that the first quarter of 2023 has seen no changes in the number of restricted shares for major shareholders[14] - The company is focused on maintaining its market position and expanding its shareholder base through strategic partnerships[12] - The first quarter report indicates a stable shareholding structure with no new major investors entering the market[14] Acquisitions and Expansion - The company acquired 100% equity of Huangshan Xin'anjiang Pharmacy Chain Co., Ltd. for RMB 32.98 million, involving 27 stores[19] - The company completed the acquisition of 70% equity of Anhui Shouzhou Huaren Pharmacy Chain Co., Ltd. for RMB 10.69 million, involving 23 stores[21] - The company has plans for market expansion in Anhui, Jiangsu, and Henan provinces, focusing on enhancing brand influence and regional leadership[16] - The company has a total of 58 self-built stores and 51 acquired stores in the Anhui province as part of its strategic expansion[17] - The company is actively developing its franchise business to strengthen its marketing network and brand presence[16] Financing Activities - The company raised a total of RMB 974.56 million from the issuance of 60.01 million A shares at a price of RMB 16.24 per share, with a net amount of RMB 879.45 million after deducting issuance costs[18] - The company is actively involved in financing and margin trading, with several major shareholders participating in these activities[13] - The company received CNY 907,734,283.02 from investment absorption, a notable increase as it was CNY 0.00 in the previous period[33] - The company paid CNY 117,479,505.06 for debt repayment, which is an increase from CNY 43,000,000.00 in the previous period, reflecting a growth of approximately 173.3%[33]

证券代码：301408 证券简称：华人健康 公告编号：2023-024 安徽华人健康医药股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、会议召开时间：2023 年 4 月 26 日（星期三）15:00-16:30 2、会议召开方式：网络互动方式 3、会议召开地点：价值在线（www.ir-online.cn） 4 、 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 4 月 26 日 前 访问网址 https://eseb.cn/13ZYbD5OC7m 或使用微信扫描下方小程序码进行会前提问，公司 将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 4 月 26 日（星期三）15:00-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长、总经理何家乐先生，董事、副总经理何家伦先生，董事、副总经理 殷俊先生、副总经理赵春水先生 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY in 2022, representing a growth of 15% compared to the previous year[1]. - The company's operating revenue for 2022 was ¥3,262,425,075.52, representing a 39.50% increase compared to ¥2,338,702,240.55 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥160,776,075.61, a significant increase of 130.58% from ¥69,726,589.16 in 2021[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥151,115,840.57, up 147.02% from ¥61,175,647.30 in 2021[17]. - The net cash flow from operating activities for 2022 was ¥173,836,654.15, an increase of 23.44% compared to ¥140,821,176.11 in 2021[17]. - The total assets at the end of 2022 were ¥2,576,184,947.30, reflecting a 30.70% increase from ¥1,971,050,723.14 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥947,278,655.70, a 20.70% increase from ¥784,801,107.10 at the end of 2021[17]. - The basic earnings per share for 2022 was ¥0.47, representing a 123.81% increase from ¥0.21 in 2021[17]. - The weighted average return on equity for 2022 was 18.54%, up from 9.30% in 2021[17]. Revenue Breakdown - The retail business segment generated a revenue of 2.232 billion CNY, with a year-on-year increase of 43.18%[41]. - The agency business reported a main revenue of 734 million CNY, growing by 24.72% year-on-year[41]. - The terminal procurement business saw a significant revenue increase to 234 million CNY, marking a 93% year-on-year growth[41]. - The company achieved online sales of ¥5.56 billion in 2022, representing a year-on-year growth of 91.2%, with O2O sales growing by 122.17% to ¥1.74 billion[47]. Market Expansion and Strategy - The company has set a revenue guidance for 2023, projecting a growth rate of 10% to 12%[1]. - New product launches are expected to contribute an additional 200 million CNY in revenue in the upcoming year[1]. - The company is expanding its market presence, targeting an increase in retail outlets by 25% in the next fiscal year[1]. - The company plans to open 518 new stores in Anhui province to strengthen its market position[55]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[145]. - Strategic partnerships with local healthcare providers are being established to improve distribution channels and customer reach[145]. Research and Development - Research and development investments have increased by 30%, focusing on innovative healthcare solutions[1]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and user experience[145]. - The number of R&D personnel increased to 40, a rise of 263.64% from the previous year, with a notable increase in the proportion of personnel holding bachelor's degrees[78]. - R&D expenses surged by 735.76% year-on-year to 4,168,358.75 yuan, reflecting a significant increase in R&D efforts[73]. Governance and Compliance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring compliance with relevant laws and regulations[121]. - The board of directors comprises 9 members, including 3 independent directors, and operates through specialized committees to ensure effective decision-making[124]. - The company has developed a comprehensive set of governance rules and operational guidelines to protect shareholders' rights and interests[122]. - The company has a robust internal financial accounting system, ensuring independent financial decision-making without shared bank accounts with the controlling shareholder[131]. Employee and Remuneration Policies - The total pre-tax remuneration for the board of directors and senior management amounted to CNY 403.23 million[154]. - The company emphasizes that the remuneration of senior management is linked to company performance and individual achievements[152]. - The company plans to implement an employee stock ownership plan to enhance the alignment of interests between employees and shareholders[164]. - The employee composition includes 4,927 sales personnel, 55 technical staff, and 56 financial staff, indicating a strong focus on sales[163]. Social Responsibility - The company donated over 80,000 RMB to social welfare initiatives during the reporting period[188]. - The company contributed nearly 7,000 RMB worth of winter supplies to support elderly individuals in a community care program[188]. - The company provided over 20,000 RMB in cooling supplies to frontline police officers during the summer[188]. - The company established a poverty alleviation initiative in collaboration with the Guizhou provincial government, purchasing over 38,000 RMB worth of beverages to aid rural revitalization[190].

股票简称：华人健康 股票代码：301408 安徽华人健康医药股份有限公司 （Anhui Huaren Health Pharmaceutical Co., Ltd.） （合肥市包河工业区上海路 18 号） 首次公开发行股票并在创业板上市 之 上市公告书 保荐机构（主承销商） （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 2023 年 2 月 1 特别提示 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书相同。 2 第一节 重要声明与提示 一、本次发行的基本情况 本公司及全体董事、监事、高级管理人员保证上市公告书的真实性、准确性、 完整性，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依法承 担法律责任。 深圳证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。 本公司提醒广大投资者认真阅读刊载于巨潮资讯网（www.cninfo.com.cn）； 中证网（www. ...

创业板风险提示 本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创 业板公司具有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成 长期、经营风险高、业绩不稳定、退市风险高等特点，投资者面临较大的市 场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因 素，审慎作出投资决定。 安徽华人健康医药股份有限公司 （Anhui Huaren Health Pharmaceutical Co., Ltd.） （合肥市包河工业区上海路 18 号） 首次公开发行股票并在创业板上市 招股说明书 保荐机构（主承销商） 发行人及全体董事、监事、高级管理人员、发行人控股股东、实际控制人 以及保荐人、承销的证券公司承诺因发行人招股说明书及其他信息披露资料有 虚假记载、误导性陈述或者重大遗漏，致使投资者在证券发行和交易中遭受损 失的，将依法赔偿投资者损失。 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据 ...

安徽华人健康医药股份有限公司 首次公开发行股票并在创业板上市 发行结果公告 保荐机构（主承销商）：华泰联合证券有限责任公司 特别提示 安徽华人健康医药股份有限公司（以下简称"华人健康"、"发行人"）首次 公开发行 60,010,000 股人民币普通股（A 股）（以下简称"本次发行"）并在创业 板上市的申请已经深圳证券交易所创业板上市委员会审议通过，并已经中国证券 监督管理委员会（以下简称"证监会"）同意注册（证监许可〔2022〕2406 号）。 本次发行的保荐机构（主承销商）为华泰联合证券有限责任公司（以下简称"保 荐机构（主承销商）"或"华泰联合证券"）发行人股票简称为"华人健康"，股 票代码为"301408"。 发行人和保荐机构（主承销商）协商确定本次发行价为 16.24 元/股，发行数 量为 60,010,000 股，全部为新股发行，无老股转让。本次发行的发行价格不超过 剔除最高报价后网下投资者报价的中位数和加权平均数以及剔除最高报价后通 过公开募集方式设立的证券投资基金、全国社会保障基金、基本养老保险基金、 根据《企业年金基金管理办法》设立的企业年金基金和符合《保险资金运用管理 办法》等规定的保险资金 ...

安徽华人健康医药股份有限公司 首次公开发行股票并在创业板上市 发行公告 保荐机构（主承销商）：华泰联合证券有限责任公司 特别提示 根据中国证监会制定的《上市公司行业分类指引》（2012 年修订），安徽华 人健康医药股份有限公司（以下简称"华人健康"、"发行人"或"公司"）所处行业 为"批发和零售业"（F），其中医药批发板块属于细分行业"批发业（F51）"；医 药零售板块属于细分行业"零售业（F52）"。截至 2023 年 2 月 14 日（T-4 日）， 中证指数有限公司发布的"批发业（F51）"及"零售业（F52）"最近一个月平均 静态市盈率为 13.33 倍及 22.35 倍。本次发行价格 16.24 元/股对应的发行人 2021 年扣除非经常性损益前后孰低的归属于母公司股东的净利润摊薄后市盈率为 106.19 倍，高于中证指数有限公司 2023 年 2 月 14 日（T-4 日）发布的"批发业 （F51）"最近一个月平均静态市盈率，超出幅度为 696.62%，也高于中证指数有 限公司 2023 年 2 月 14 日（T-4 日）发布的"零售业（F52）"最近一个月平均静 态市盈率，超出幅度为 375.1 ...